XLO vs. FATE, KYTX, BDTX, VXRT, LXEO, LYEL, BYSI, NMRA, NKTX, and FTLF
Should you be buying Xilio Therapeutics stock or one of its competitors? The main competitors of Xilio Therapeutics include Fate Therapeutics (FATE), Kyverna Therapeutics (KYTX), Black Diamond Therapeutics (BDTX), Vaxart (VXRT), Lexeo Therapeutics (LXEO), Lyell Immunopharma (LYEL), BeyondSpring (BYSI), Neumora Therapeutics (NMRA), Nkarta (NKTX), and FitLife Brands (FTLF). These companies are all part of the "pharmaceutical products" industry.
Xilio Therapeutics vs. Its Competitors
Xilio Therapeutics (NASDAQ:XLO) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.
Xilio Therapeutics has higher earnings, but lower revenue than Fate Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Fate Therapeutics had 3 more articles in the media than Xilio Therapeutics. MarketBeat recorded 5 mentions for Fate Therapeutics and 2 mentions for Xilio Therapeutics. Fate Therapeutics' average media sentiment score of 0.55 beat Xilio Therapeutics' score of 0.23 indicating that Fate Therapeutics is being referred to more favorably in the news media.
Xilio Therapeutics presently has a consensus target price of $4.00, indicating a potential upside of 477.20%. Fate Therapeutics has a consensus target price of $3.83, indicating a potential upside of 234.79%. Given Xilio Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Xilio Therapeutics is more favorable than Fate Therapeutics.
Xilio Therapeutics has a net margin of -585.54% compared to Fate Therapeutics' net margin of -1,318.93%. Fate Therapeutics' return on equity of -47.17% beat Xilio Therapeutics' return on equity.
Xilio Therapeutics has a beta of -0.15, indicating that its stock price is 115% less volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500.
54.3% of Xilio Therapeutics shares are held by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are held by institutional investors. 5.2% of Xilio Therapeutics shares are held by company insiders. Comparatively, 5.5% of Fate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Fate Therapeutics beats Xilio Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Xilio Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for XLO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding XLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Xilio Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:XLO) was last updated on 7/5/2025 by MarketBeat.com Staff
Free XLO Stock Alerts